en COVID-19 is a life-threatening condition due to a hyperactive immune reaction to SARS-CoV-2 infection, for which no effective treatment is available so far. Based on the regenerative and immune-modulatory properties of mesenchymal stromal cells (MSCs), in collboration with dr. Rachele Ciccocioppo, we treated, for the first time in Europe a 69-year-old man admitted at the Intensive Care Unit of University Hospital, Verona, for COVID-related respiratory failure with two intravenous infusions of allogeneic umbilical cord-derived MSCs. We detected a significant reduction in serum levels of pro-inflammatory cytokines, paralleled by an increase of several growth factors. Our results provided the first evidence of the safety and feasibility to use MSC to control the immunoalteration as a part of the COVID-19 disease.